Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials

被引:111
作者
Hopper, Ingrid [2 ]
Billah, Baki
Skiba, Marina [2 ]
Krum, Henry [1 ,2 ]
机构
[1] Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Dept Epidemiol & Prevent Med, Alfred Ctr, Melbourne, Vic 3004, Australia
[2] Monash Univ, Alfred Hosp, Dept Clin Pharmacol, Melbourne, Vic 3181, Australia
来源
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION | 2011年 / 18卷 / 06期
基金
英国医学研究理事会;
关键词
Prediabetes; myocardial infarction; stroke; meta-analysis; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; FASTING GLUCOSE; MELLITUS; ACARBOSE; METFORMIN; MORTALITY; INDIVIDUALS; PROGRESSION; PEOPLE;
D O I
10.1177/1741826711421687
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are pre-diabetic states, treatment of which may prevent or delay the onset of overt diabetes and thus potentially reduce major cardiovascular (CV) events. We therefore sought to determine whether interventions (including diet, exercise and pharmacological therapy), altered all-cause and cardiovascular related mortality in such subjects. Methods: We performed a meta-analysis of prospective, randomised controlled trials (RCTs) that were identified in the medical literature and databases. Trials were eligible for inclusion if they reported all-cause mortality rates (at a minimum), recruited approximately 100 patients and had a minimum follow-up of one year. Interventions were divided into pharmacological and non-pharmacological. Results: Ten RCTs that enrolled 23,152 patients met the above entry criteria. Trials ran for an average of 3.75 years. Diabetes was delayed or prevented by these interventions vs control (risk ratio 0.83, 95%CI 0.80-0.86). Non-drug approaches (n = 3495) were superior to drug-based approaches (n = 20,872) in diabetes prevention (0.52, 0.46-0.58 vs 0.70, 0.58-0.85, P < 0.05). There was no difference in risk of all-cause mortality in the intervention versus control group (0.96, 0.84-1.10) and no difference in CV death (1.04, 0.61-1.78). There was a non-significant trend towards reduction in fatal and non-fatal myocardial infarction (0.59, 0.23-1.50). Fatal and non-fatal stroke was borderline reduced (0.76, 0.58-0.99) with intervention versus control. Conclusions: Despite interventions being mostly successful in retarding progression to overt diabetes, this did not result in reductions in all-cause or cardiovascular mortality, or myocardial infarction, with the possible exception of stroke.
引用
收藏
页码:813 / 823
页数:11
相关论文
共 37 条
[1]  
[Anonymous], 2010, DIABETES CARE, DOI DOI 10.2337/dc10-s062
[2]  
[Anonymous], LANCET
[3]  
[Anonymous], 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation
[4]   Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance - The Australian diabetes, obesity, and lifestyle study (AusDiab) [J].
Barr, Elizabeth L. M. ;
Zimmet, Paul Z. ;
Welborn, Timothy A. ;
Jolley, Damien ;
Magliano, Dianna J. ;
Dunstan, David W. ;
Cameron, Adrian J. ;
Dwyer, Terry ;
Taylor, Hugh R. ;
Tonkin, Andrew M. ;
Wong, Tien Y. ;
McNeil, John ;
Shaw, Jonathan E. .
CIRCULATION, 2007, 116 (02) :151-157
[5]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[6]  
Bosch J, 2006, NEW ENGL J MED, V355, P1551
[7]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[8]   Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Ttrial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (04) :486-494
[9]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[10]  
Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743